Print this page
breast
-
Evolution and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in Breast Tumor Microenvironment.
Protocol: 001839Principal Investigator:
-
Shridar Ganesan
Applicable Disease Sites: Breast -
Impact of Early Radiation Oncology Involvement as Part of a Multidisciplinary Palliative Care Team on Quality of Life Among Diverse Patients with Advanced/Metastatic Malignancies.
Protocol: 002168Principal Investigator:
-
Malcolm Mattes
Applicable Disease Sites: Any Site -
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma.
Protocol: 011909Principal Investigator:
-
Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase II/III Randomized Study of R-miniCHOP With or Without Oral Azacitidine (CC-486) in Participants Age 75 years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements.
Protocol: 012103Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase Ib, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Glofitamab Following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
Protocol: 012107Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Fitness-Adapted, Pembrolizumab-Based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above.
Protocol: 012203Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma -
A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma.
Protocol: 012207Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Any Site -
Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
Protocol: 012302Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
-
Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma.
Protocol: 012312Principal Investigator:
-
Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.
Protocol: 012314Principal Investigator:
-
Joanna Rhodes
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 2 Study of Mosunetuzumab with Lenalidomide Augmentation as First-Line Therapy for Follicular and Marginal Zone Lymphoma.
Protocol: 012319Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma.
Protocol: 012320Principal Investigator:
-
Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma.
Protocol: 012403Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults.
Protocol: 022101Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP- 5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation.
Protocol: 022303Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Leukemia, other